Article Sidebar

PDF
Date Published: 27/06/2023
Abstract Views: 121
Views PDF: 80
DOI: https://doi.org/10.51298/vmj.v527i1B.5785
Issue
Vol. 527 No. 1B (2023)
Section
Các bài báo
How to Cite
Nguyễn, K. T., Phạm, T. H., Cấn, X. H., & Nguyễn, V. N. (2023). EVALUATING TREATMENT RESPONSE, SURVIVAL OF STAGE IV NON SMALL CELL LUNG CANCER BY PEMETREXED – CARBOPLATIN REGIMEN. Vietnam Medical Journal, 527(1B). https://doi.org/10.51298/vmj.v527i1B.5785

EVALUATING TREATMENT RESPONSE, SURVIVAL OF STAGE IV NON SMALL CELL LUNG CANCER BY PEMETREXED – CARBOPLATIN REGIMEN

Khánh Toàn Nguyễn1, Thị Hường Phạm1,, Xuân Hạnh Cấn2, Văn Nhật Nguyễn3
1 Oncology Hospital Nghe An
2 National lung hospital
3 Nghe An Oncology Hospital

Main Article Content

Abstract

Aims: To evaluate response and survival of patients with stage IV Non small cell lung cancer who were treated by Pemetrexed – Carboplatin regimen. Patients and method of study: Retrospective and prospective study on 45 non-small cell lung cancer patients in stage IV treated by Pemetrexed - Carboplatin regimen  from August 2018 to August 2021. Results: Median of age 59,2 ± 7,4, male/female: 5,4/1. 39/45 (89,7%) patients completed four cycles, and 30/45 (66,7%) completed six cycles of chemotherapy. Objective response rate is 37,8%; disease control rate is 66,7%. Performance status and age are factors affecting response rate. The mean progression-free survival (PFS) was 7.4 ± 0.3 months, the median PFS was 7.7 months. The mean overall survival (OS) was 20.5 ± 1.9 months, the median OS was 19 months. Conclusion: Pemetrexed- Carboplatin regimen is effective in the treatment of stage IV non small cell lung cancer.

Article Details

Keywords

Non small cell lung cancer, stage IV, Pemetrexed Carboplatin

References

1. Sung H, Ferlay J, Siegel RL. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. May 2021;71(3):209-249. doi:10.3322/caac.21660
2. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. Dec 1 2005;104(11):2449-56. doi:10.1002/cncr.21480
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Jul 20 2008;26(21):3543-51. doi:10.1200/jco.2007.15.0375
4. Ito M, Horita N. Carboplatin plus pemetrexed for the elderly incurable chemo-naive nonsquamous non-small cell lung cancer: Meta-analysis. Apr 2019;15(2):e3-e10. doi:10.1111/ ajco.12837
5. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. Journal of the National Cancer Institute. Jun 6 2007;99(11):847-57. doi:10.1093/jnci/djk196
6. Wang W, Shang L, Li X, Li J, Wen F, Liu J. [Pemetrexed combined with cisplatin or carboplatin regimen in the treatment of advanced recurrent or metastasis non-small cell lung cancer: analysis of 63 cases]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. Jan 2011; 14 (1):54-7. doi:10.3779/j.issn.1009-3419. 2011.01.11
7. Trần Thanh Hà. Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ giai đoạn IV bằng phác đồ pemetrexed – carboplatin tại bệnh viện K. Trường Đại học Y Hà Nội; 2018.
8. Katirtzoglou N, Gkiozos I, Makrilia N, et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clinical lung cancer. Jan 2010;11(1):30-5. doi:10.3816/ CLC.2010.n.005